<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307489</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-174-0106</org_study_id>
    <nct_id>NCT00307489</nct_id>
  </id_info>
  <brief_title>Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adefovir Dipivoxil for Chronic Hepatitis B and Having Persistent Viral Replication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once
      daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg
      (FTC/TDF) once daily in subjects currently being treated with adefovir dipivoxil (Hepsera)
      for chronic hepatitis B who have persistent viral replication (detectable hepatitis B virus
      deoxyribonucleic acid [HBV DNA]).

      Subjects with confirmed (within 4 weeks) plasma HBV DNA ≥ 400 copies/mL during double blind
      treatment at Week 24 or any time thereafter have the option of receiving 12 weeks of
      open-label FTC/TDF which may be continued through the end of the 168-week treatment period if
      there is a virologic response (HBV DNA &lt; 400 copies/mL). Alternatively, subjects with
      confirmed HBV DNA &lt; 400 copies/mL at or any time after Week 24 of double-blind treatment may
      continue blinded therapy up to Week 168 at the discretion of the investigator. If, in the
      investigator's opinion, it is felt that continued blinded treatment beyond 24 weeks in
      subjects with confirmed HBV DNA ≥ 400 copies/mL is not beneficial, the subject may
      discontinue the study and begin commercially available HBV therapy rather than initiate
      open-label FTC/TDF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Plasma HBV DNA &lt; 169 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Plasma HBV DNA &lt; 400 Copies/mL at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 Plasma HBV DNA Levels at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal ALT at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>ULN for males = 43 U/L; 34 U/L for females</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalized ALT at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Subjects with elevated ALT at baseline that return to normal by Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Early Antigen (HBeAg) Loss at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg Seroconversion at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg Loss at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 Plasma HBV DNA Levels at Week 168</measure>
    <time_frame>168 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168</measure>
    <time_frame>168 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HBV DNA &lt; 400 Copies/mL at Week 168</measure>
    <time_frame>168 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal ALT at Week 168</measure>
    <time_frame>168 weeks</time_frame>
    <description>ULN for males = 43 U/L; ULN for females = 34 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normalized ALT at Week 168</measure>
    <time_frame>168 weeks</time_frame>
    <description>Subjects with elevated ALT at baseline that return to normal by Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Early Antigen (HBeAg) Loss at Week 168</measure>
    <time_frame>168 weeks</time_frame>
    <description>Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168</measure>
    <time_frame>168 weeks</time_frame>
    <description>Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg Loss at Week 168</measure>
    <time_frame>168 weeks</time_frame>
    <description>Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HBV DNA &lt; 169 Copies/mL at Week 168</measure>
    <time_frame>168 weeks</time_frame>
    <description>P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC/TDF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir DF</intervention_name>
    <description>300 mg tablet, once daily (QD)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine /tenofovir DF</intervention_name>
    <description>emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 through 69 years of age, inclusive

          -  Chronic HBV infection, defined as positive serum HBsAg for at least 6 months

          -  Active chronic HBV infection with all the following:

               1. Currently treated with adefovir dipivoxil 10 mg QD (for at least 24 weeks but not
                  more than 96 weeks)

               2. HBeAg positive or negative at screening

               3. Plasma HBV DNA &gt;/= 1000 copies/mL at screening (irrespective of HBeAg status)

               4. Serum ALT less than 10 times the upper limit of normal (ULN)

               5. Calculated creatinine clearance of at least 70 mL/min using the Cockcroft-Gault
                  formula

               6. Hemoglobin at least 8 g/dL

               7. Neutrophils at least 1,000 /mm3

          -  Nucleoside naive except for lamivudine (&gt;/= 12 weeks of therapy)

          -  Negative serum beta human chorionic gonadotropin

          -  Compliant with adefovir dipivoxil

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Pregnant women, women who are breastfeeding or who believe they may wish to become
             pregnant during the course of the study

          -  Male or females of reproductive potential who are unwilling to use an effective method
             of contraceptive while enrolled in the study. For males, condoms should be used and
             for females, a barrier contraception method should be used

          -  Decompensated liver disease defined as conjugated bilirubin greater than 1.5 times
             ULN, prothrombin time (PT) greater than 1.5 times ULN, platelets less than 75,000/mm3,
             serum albumin less than 3.0 g/dL, or prior history of clinical hepatic decompensation
             (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)

          -  Prior use of tenofovir DF or entecavir

          -  Received treatment with interferon or pegylated interferon within 6 months of the
             screening visit

          -  Evidence of hepatocellular carcinoma (HCC); for example, alpha-fetoprotein greater
             than 50 ng/mL or by any other standard of care measure.

          -  Co-infection with HCV (based on serology), human immunodeficiency virus (HIV), or
             hepatitis delta virus (HDV)

          -  Significant renal, cardiovascular, pulmonary, or neurological disease.

          -  Received solid organ or bone marrow transplantation.

          -  Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.),
             investigational agents, nephrotoxic agents, or agents capable of modifying renal
             excretion

          -  Has proximal tubulopathy

          -  Known hypersensitivity to the study drugs (tenofovir DF or emtricitabine/tenofovir
             DF), the metabolites (tenofovir or emtricitabine) or formulation excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Rossi, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20999</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006 Aug;44(2):318-25.</citation>
    <PMID>16871563</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.</citation>
    <PMID>19052126</PMID>
  </results_reference>
  <results_reference>
    <citation>Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol. 2008 Mar;48(3):383-6. doi: 10.1016/j.jhep.2007.12.006. Epub 2007 Dec 31.</citation>
    <PMID>18191272</PMID>
  </results_reference>
  <results_reference>
    <citation>Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008 Mar;48(3):391-8. doi: 10.1016/j.jhep.2007.09.020. Epub 2008 Jan 3.</citation>
    <PMID>18199519</PMID>
  </results_reference>
  <results_reference>
    <citation>van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010 Jan;51(1):73-80. doi: 10.1002/hep.23246.</citation>
    <PMID>19998272</PMID>
  </results_reference>
  <results_reference>
    <citation>Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20.</citation>
    <PMID>20600025</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <results_first_submitted>January 30, 2009</results_first_submitted>
  <results_first_submitted_qc>May 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2009</results_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 106 subjects were randomized (105 of which were subsequently treated) across 28 study centers in the US, Germany, France and Spain between 24 April 2006 and 07 March 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir DF</title>
          <description>tenofovir DF 300 mg QD</description>
        </group>
        <group group_id="P2">
          <title>Emtricitibine/Tenofovir DF</title>
          <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Through Week 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">16 of the 52 subjects switched to open-label FTC/TDF prior to Week 48.</participants>
                <participants group_id="P2" count="50">9 of the 50 subjects switched to open-label FTC/TDF prior to Week 48.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 48 Through Week 168</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46">11 of the 46 subjects switched to open-label FTC/TDF prior to Week 168.</participants>
                <participants group_id="P2" count="44">5 of the 44 subjects switched to open-label FTC/TDF prior to Week 168.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seroconversion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir DF</title>
          <description>tenofovir DF 300 mg QD</description>
        </group>
        <group group_id="B2">
          <title>Emtricitibine/Tenofovir DF</title>
          <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="11.4"/>
                    <measurement group_id="B2" value="39" spread="10.4"/>
                    <measurement group_id="B3" value="39" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Lamivudine Experience</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HBV DNA</title>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.06" spread="1.430"/>
                    <measurement group_id="B2" value="5.87" spread="1.779"/>
                    <measurement group_id="B3" value="5.97" spread="1.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Plasma HBV DNA &lt; 169 Copies/mL at Week 48</title>
        <time_frame>48 weeks</time_frame>
        <population>Randomized and Treated (RAT) subjects at Week 48 - Non-Completers=Failure (ie, includes subjects who switched to open-label FTC/TDF at or after Week 24)</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HBV DNA &lt; 169 Copies/mL at Week 48</title>
          <population>Randomized and Treated (RAT) subjects at Week 48 - Non-Completers=Failure (ie, includes subjects who switched to open-label FTC/TDF at or after Week 24)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5"/>
                    <measurement group_id="O2" value="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.544</p_value>
            <p_value_desc>P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in log10 Plasma HBV DNA Levels at Week 48</title>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 Plasma HBV DNA Levels at Week 48</title>
          <population>RAT Analysis Set</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.58" spread="1.290"/>
                    <measurement group_id="O2" value="-3.34" spread="1.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>van Elteren</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48</title>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48</title>
          <population>RAT Analysis Set</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.6" spread="54.53"/>
                    <measurement group_id="O2" value="-41.4" spread="151.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <p_value_desc>Controlling for baseline HBeAg and prior lamivudine use.</p_value_desc>
            <method>van Elteren</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Plasma HBV DNA &lt; 400 Copies/mL at Week 48</title>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HBV DNA &lt; 400 Copies/mL at Week 48</title>
          <population>RAT Analysis Set Non-Completers=Failure</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.988</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal ALT at Week 48</title>
        <description>ULN for males = 43 U/L; 34 U/L for females</description>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal ALT at Week 48</title>
          <description>ULN for males = 43 U/L; 34 U/L for females</description>
          <population>RAT Analysis Set Non-Completers=Failure</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.423</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normalized ALT at Week 48</title>
        <description>Subjects with elevated ALT at baseline that return to normal by Week 48.</description>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set - subjects with ALT above ULN at baseline. Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normalized ALT at Week 48</title>
          <description>Subjects with elevated ALT at baseline that return to normal by Week 48.</description>
          <population>RAT Analysis Set - subjects with ALT above ULN at baseline. Non-Completers=Failure</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B Early Antigen (HBeAg) Loss at Week 48</title>
        <description>Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.</description>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set with Positive HBeAg at Baseline. Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Early Antigen (HBeAg) Loss at Week 48</title>
          <description>Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.</description>
          <population>RAT Analysis Set with Positive HBeAg at Baseline. Non-Completers=Failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.952</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlling for baseline HBeAg and prior lamivudine use.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBeAg Seroconversion at Week 48</title>
        <description>Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline.</description>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set with Positive Baseline HBeAg. Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>HBeAg Seroconversion at Week 48</title>
          <description>Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline.</description>
          <population>RAT Analysis Set with Positive Baseline HBeAg. Non-Completers=Failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBsAg Loss at Week 48</title>
        <description>Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.</description>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>HBsAg Loss at Week 48</title>
          <description>Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.</description>
          <population>RAT Analysis Set Non-Completers=Failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48</title>
        <description>Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline.</description>
        <time_frame>48 Weeks</time_frame>
        <population>RAT Analysis Set Non-Completers=Failure</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48</title>
          <description>Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline.</description>
          <population>RAT Analysis Set Non-Completers=Failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in log10 Plasma HBV DNA Levels at Week 168</title>
        <time_frame>168 weeks</time_frame>
        <population>Non-completers = failure analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 Plasma HBV DNA Levels at Week 168</title>
          <population>Non-completers = failure analysis</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.79" spread="1.305"/>
                    <measurement group_id="O2" value="-3.48" spread="1.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.103</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>van Elteren</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168</title>
        <time_frame>168 weeks</time_frame>
        <population>Non-completers = failure analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168</title>
          <population>Non-completers = failure analysis</population>
          <units>U/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="60.23"/>
                    <measurement group_id="O2" value="-54.5" spread="141.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>van Elteren</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HBV DNA &lt; 400 Copies/mL at Week 168</title>
        <time_frame>168 weeks</time_frame>
        <population>Non-completers = failure analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HBV DNA &lt; 400 Copies/mL at Week 168</title>
          <population>Non-completers = failure analysis</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                    <measurement group_id="O2" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.781</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal ALT at Week 168</title>
        <description>ULN for males = 43 U/L; ULN for females = 34 U/L</description>
        <time_frame>168 weeks</time_frame>
        <population>Non-completers = failure analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal ALT at Week 168</title>
          <description>ULN for males = 43 U/L; ULN for females = 34 U/L</description>
          <population>Non-completers = failure analysis</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0"/>
                    <measurement group_id="O2" value="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.936</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normalized ALT at Week 168</title>
        <description>Subjects with elevated ALT at baseline that return to normal by Week 48.</description>
        <time_frame>168 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normalized ALT at Week 168</title>
          <description>Subjects with elevated ALT at baseline that return to normal by Week 48.</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.784</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B Early Antigen (HBeAg) Loss at Week 168</title>
        <description>Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.</description>
        <time_frame>168 weeks</time_frame>
        <population>Non-completer = Failure Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Early Antigen (HBeAg) Loss at Week 168</title>
          <description>Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.</description>
          <population>Non-completer = Failure Analysis</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.703</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168</title>
        <description>Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.</description>
        <time_frame>168 weeks</time_frame>
        <population>Non-completer = Failure Analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168</title>
          <description>Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.</description>
          <population>Non-completer = Failure Analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.254</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBsAg Loss at Week 168</title>
        <description>Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.</description>
        <time_frame>168 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>HBsAg Loss at Week 168</title>
          <description>Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.254</p_value>
            <p_value_desc>Controlling for baseline HBeAg status and prior lamivudine use.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HBV DNA &lt; 169 Copies/mL at Week 168</title>
        <description>P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.</description>
        <time_frame>168 weeks</time_frame>
        <population>Non-completers = failure analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>tenofovir DF 300 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Emtricitibine/Tenofovir DF</title>
            <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HBV DNA &lt; 169 Copies/mL at Week 168</title>
          <description>P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.</description>
          <population>Non-completers = failure analysis</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>168 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir DF</title>
          <description>tenofovir DF 300 mg QD</description>
        </group>
        <group group_id="E2">
          <title>Emtricitibine/Tenofovir DF</title>
          <description>emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroadenoma of Breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Waldenstrom's Macroglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49"/>
                <counts group_id="E2" subjects_affected="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title vocab="Dizziness">Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The randomized and treated (RAT) analysis set includes all subjects who were ongoing at the time of analysis (i.e., those on blinded therapy and those who switched to open-label FTC/TDFdue to persistent viremia).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stephen J. Rossi, PharmD</name_or_title>
      <organization>Gilead Sciences, Inc.</organization>
      <phone>650-522-4212</phone>
      <email>stephen.rossi@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

